{"id":967200,"date":"2026-05-27T06:34:01","date_gmt":"2026-05-27T10:34:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/apogee-therapeutics-announces-1-3-billion-strategic-financing-collaboration-with-blackstone-life-sciences-to-advance-phase-3-development-and-commercialization-of-zumilokibart\/"},"modified":"2026-05-27T06:34:01","modified_gmt":"2026-05-27T10:34:01","slug":"apogee-therapeutics-announces-1-3-billion-strategic-financing-collaboration-with-blackstone-life-sciences-to-advance-phase-3-development-and-commercialization-of-zumilokibart","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/apogee-therapeutics-announces-1-3-billion-strategic-financing-collaboration-with-blackstone-life-sciences-to-advance-phase-3-development-and-commercialization-of-zumilokibart\/","title":{"rendered":"Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart"},"content":{"rendered":"
\n

\n Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debt\u00a0<\/em>\n <\/p>\n

\n Combined with company’s current total cash of $1.3 billion, this transaction positions Apogee to achieve a self-sustainable financial profile through commercialization of zumilokibart without need for future equity financing<\/em>\n <\/p>\n

\n Apogee to host webcast with the APEX Phase 2 Part B results today at 8:00 a.m. Eastern Time<\/em>\n <\/p>\n

SAN FRANCISCO and BOSTON, May 27, 2026 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced that it has entered into a strategic financing collaboration with funds managed by Blackstone Life Sciences (\u201cBlackstone\u201d) for up to $1.3 billion in flexible, non-dilutive total capital to support the continued development and potential commercialization of zumilokibart.<\/p>\n

\u201cOur partnership with Blackstone Life Sciences represents a major milestone in the advancement of zumilokibart as the next meaningful first line therapy for moderate-to-severe atopic dermatitis,\u201d said Michael Henderson, M.D., Chief Executive Officer of Apogee Therapeutics. \u201cThis collaboration provides non-dilutive flexible funding at an attractive cost of capital for the late-stage development of zumilokibart and establishes a path to commercialization and profitability for Apogee. As supported by our Apex Part B data announced today, we believe zumilokibart has the potential to be a transformative therapy for patients with differentiated efficacy and dosing in atopic dermatitis and other large I&I indications.\u201d<\/p>\n

\u201cWe are excited to support Apogee’s advancement of zumilokibart through Phase 3 development and potential commercialization,\u201d said Dr. Nicholas Galakatos, Global Head of Blackstone Life Sciences. \u201cOur collaboration with Apogee is a great example of our strategy to provide leading biotechnology companies with non-dilutive financing at scale and the resources and flexibility to further scientific innovation and invest in the advancement of their pipelines.”<\/p>\n

Added Kiran Reddy, M.D., Senior Managing Director, Blackstone Life Sciences, “This is the largest royalty financing for a pre-Phase 3 program to date. It reflects our conviction that zumilokibart has the potential to become a highly differentiated, multi-indication product that will have a major impact on patients’ quality of life.”<\/p>\n

Transaction Overview<\/strong><\/p>\n

The collaboration agreement provides for up to $1.3 billion in flexible, non-dilutive total capital, including up to $800 million of synthetic royalty and up to $500 million of senior debt available at the mutual consent of Apogee and Blackstone.<\/p>\n

\n Synthetic royalty: <\/strong>Blackstone will provide up to $800 million of synthetic royalty funding in exchange for low-to-mid single digit tiered royalties for a term of 15 years on worldwide annual sales of zumilokibart. The royalties decrease based on sales with no royalties on global annual sales in excess of $8 billion.<\/p>\n